Background: The use of Mohs micrographic surgery (MMS) has increased greatly to treat basal cell and cutaneous squamous cell carcinomas (keratinocyte carcinoma [KC]), and consensus-based Appropriate Use Criteria (AUC) were developed to identify tumors for which MMS is appropriate.
Skin cancer treatments in the United States increased approximately 50% from 1996 to 2008, 1 but the use of Mohs micrographic surgery (MMS) increased 400% from 1995 to 2009. 2, 3 Few rigorous studies have compared recurrence outcomes after different treatments for basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC), collectively called keratinocyte carcinoma (KC). In a randomized clinical trial of high-risk BCCs on the face, 10-year tumor recurrence rates were somewhat lower after MMS than after excision (4.4% vs. 12.2%, respectively; P = .1), but for most primary KCs, no empiric study has demonstrated for which tumors MMS is superior. [4] [5] [6] [7] To guide clinicians, Appropriate Use Criteria (AUC) for MMS were developed by the American Academy of Dermatology and dermatologic surgery societies. 3 Using a modified Delphi exercise, 8 a 17-member panel reviewed 270 clinical scenarios that contained different patient and skin cancer characteristics and rated them as appropriate, inappropriate, or uncertain for MMS. 3 The AUC define MMS as one appropriate treatment for such tumors, but the document acknowledges that other acceptable approaches may also exist.
We sought to learn if the AUC would identify KCs for which MMS is superior to other treatments in preventing tumor recurrence. We applied the AUC to a large consecutive cohort of patients with KC to determine, among tumors judged appropriate for MMS, if tumor recurrence differed after different treatments. We hypothesized that in this more targeted subgroup, recurrence rates after MMS would be significantly lower than after other treatments.
METHODS
Design, setting, patients, and baseline data This study was nested within a prospective cohort study of all patients with KC in 1999 or 2000 treated at a university-based dermatology clinic (UNIV) or the affiliated Veterans Affairs dermatology clinic. The parent study compared outcomes after different therapies of all tumors diagnosed over the 2-year period; the current study was limited only to tumors judged appropriate for MMS using the AUC. This study was approved by local institutional review boards. We obtained patient informed consent when required.
The parent study has been previously described in detail. 4 In brief, eligible patients for this study were histopathologically diagnosed with BCC or SCC at a primary skin site. The date of diagnosis was the date that the initial biopsy specimen was obtained from the KC. Treatment with MMS and excision occurred during specialized clinics.
Collection of outcome data
The primary source of data on recurrence was the medical record, which was reviewed by dermatologic nurse practitioners at a median of 9.0 years after initial treatment. Typically, they were not aware of treatment when reviewing pathology records, although they may have learned the treatment as they reviewed the record. Consenting patients were reexamined by a dermatologist blinded to treatment type at a median of 8.6 years after initial treatment. If either the record review or examination indicated a tumor recurrence, the record was reviewed again by a dermatologic clinician blinded to the original review (to validate the outcome). Follow-up ended at the last date when the patient received care. A patient was lost to follow-up if there was no record of care after treatment.
Measures
Primary outcome. A tumor was defined as recurrent if either of these criteria was met: 1) if the tumor type (BCC or SCC) and body location were identical to those of the primary tumor, and the lesion was described by the clinician as recurrent or previously treated or 2) if the tumor type was identical to the primary tumor and the tumor location was very close to or the same as the original body site, using clinical notes, maps, and diagrams in the record. 4 The date of recurrence was the date the biopsy specimen was obtained from the recurrent lesion.
Patient and tumor characteristics. The primary source for patient and tumor characteristics was the medical record; data on comorbidity were obtained by patient survey. We collected data on age, sex, previous KCs, number of tumors at presentation, care site, genetic syndromes (basal cell nevus 3 This review was blinded to treatment type. Judgment was required for classification of 7 patients because they could have been classified into 2 AUC categories. In these situations, we classified patients into the category in which recurrence was more likely. For example, patients who were both immunocompromised and had previous radiation were classified as ''prior radiation.'' Similarly, judgment was required for classification of some tumors because records did not contain information required for categorization or because tumors fell into 2 categories. For example, tumor size was missing for 206 of 1483 tumors (13.9%), but assumption of the largest or smallest criterion for size did not change the AUC categorization for any tumor; for tumors with missing size, we used multiply imputed tumor sizes as described in the analytic strategy below. Breslow depth was not noted on the pathology reports for any tumor; Clark level was noted in the charts for only 3% of SCCs.
Analytic strategy
Statistical analyses were performed using SAS software (version 9.4; SAS Institute, Inc, Cary, NC). Within the group of tumors judged to be appropriate for MMS, our overall strategy was to describe differences in patients and tumors treated with MMS or other treatments; to compare patient, tumor, and treatment characteristics in tumors that recurred or did not recur after treatment; and to compare 5-year recurrence rates after different treatments in unadjusted and adjusted models.
We compared treatment with or without MMS using chi-square tests for categorical characteristics and nonparametric Wilcoxon tests for continuous characteristics.
We performed adjusted Cox models to calculate 5-year recurrence rates after adjustment for characteristics likely related to recurrence. Cumulative incidence plots (with data right-censored at the last date of care) were used to display cumulative incidence of tumor recurrence. Potential predictors of recurrence included in the models were age, sex, care site, annual number of dermatology visits, history of KC, history of HIV, number of tumors at presentation, tumor histopathologic category (ie, aggressive BCC, superficial/nodular BCC, invasive SCC, SCC in situ), tumor body location, and tumor size. Pathology records noted NCCN histopathologic risk factors for recurrence much more commonly at UNIV than the Veterans Affairs clinic; this variable was colinear with care site and was not included in the models. We also performed similar models with fewer predictors; because the results were similar, we present the more comprehensive models below. 12 A Cox proportional hazard model was developed in the tumors treated with excision or MMS because the indications for these treatment methods are similar 11 and because patients and tumors treated with other modalities were different. 4 The HubereWhite method was used to adjust for intrapatient correlation in the Cox models (for those with [1 tumor).
We used multiple imputation for tumor size to include all observations in the Cox models. 13 Specifically, tumor size was predicted using a linear regression on age, sex, location in the H zone of the face, 14 history of KC, histopathologic type, squamous cell carcinoma UNIV: university-based dermatology clinic J AM ACAD DERMATOL VOLUME 76, NUMBER 6 histopathologic category, and number of tumors at presentation. We used 100 imputed data sets to ensure estimates had acceptably small levels of Monte Carlo error.
RESULTS

Patient, tumor, and care characteristics
Of the 1992 tumors in the cohort, 1483 tumors (74%) were classified as appropriate, 121 (6%) as uncertain, and 388 (19%) as inappropriate for MMS (Supplemental Fig 1; available at http://www.jaad. org). Of the entire cohort, 34% were treated with MMS. Of tumors classified as appropriate, 45% were treated with MMS.
Compared with other patients, patients whose tumors were treated with MMS were much more likely to be female and to be treated at UNIV (P \ .0001). Compared with other tumors, tumors treated with MMS were smaller and more likely to be located in the H area 3 (P \ .0001). They were also more likely to be aggressive BCCs than nodular or superficial BCCs. Most SCCs were treated by other treatments, although MMS was more likely to be used for invasive SCCs than for SCC in situ (P \ .0001). Overall, MMS was more likely for tumors for which NCCN histopathologic risk factors for recurrence were noted (P = .0006; Table I ).
Tumor recurrence
Follow-up was available for [90% of tumors at a median of 7.4 years (range, 3.0-8.8 years) after treatment. 4 Duration of follow-up did not differ Hazard of tumor recurrence at 5 years after MMS compared to excision ; P = .02). Larger tumors were somewhat less likely to recur (P = .06), and the HR of tumor recurrence after MMS compared to excision was 0.6 (95% CI, 0.3-1.0; P = .07).
DISCUSSION
In this application of the AUC to a prospective cohort of 1536 consecutive patients with 1992 KCs, 74% of tumors were classified as appropriate for MMS. Of tumors judged appropriate for MMS, overall the 5-year recurrence rate after treatment was 3.1% (N = 57); in tumors treated with either MMS or excision, the HR of tumor recurrence after MMS was somewhat less than after excision (0.6 [95% CI, 0.3-1.0]; P = .06).
Comparison with previous studies
Previous applications of the AUC to university dermatology practices had similar percentages of appropriate, inappropriate, and uncertain categorizations, and of the tumors deemed appropriate, similar percentages of referral for MMS. 15, 16 To our knowledge, no previous study has compared tumor recurrence outcomes after different treatments in the subgroup of tumors judged appropriate for MMS. 17 Rigorous cohort and randomized studies comparing recurrence of primary KC after different treatments have consistently demonstrated lower recurrence rates after MMSdalthough typically not statistically significantly lower. [4] [5] [6] [7] For example, unadjusted, adjusted, and propensity-adjusted analyses of the complete cohort from which the current data were derived demonstrated HRs for 5-year recurrence after MMS compared to excision of around 0.6, but with confidence limits that always crossed 1. 4 In prospective studies, reduction in recurrence rates after MMS compared to excision has been of borderline statistical significance in certain clinical subgroups of tumors. In a randomized controlled trial in high-risk primary BCCs of the face, 10-year recurrence rates were 4.4% after MMS and 12.2% after excision (P = .1). 7 Similarly, in the complete cohort from which the current data were derived, for tumors in the H zone of the face, recurrence was less likely after MMS than after excision (1.2% vs. 6.3%, respectively; P = .05) at the UNIV site. 4 The AUC sought to ''provide guidance for the rational use of MMS in the practice setting'' but not to dictate a standard of care. 3 The AUC also did not include other treatment modalities. 3 The current results show that in a sample of KCs judged appropriate for MMS using the AUC, tumor recurrence over median follow-up of 7.4 years was somewhat lower in tumors treated with MMS than in those treated with excision.
Our findings inform this guidance provided by the AUC on the use of MMS in the practice setting. We noted a 2% point difference in unadjusted 5-year recurrence rates between MMS and excision (ie, 50 KCs would need to be treated with MMS rather than excision to prevent a single tumor recurrence at 5 years). The clinical significance of this 2% point difference depends on individual patient characteristics and patient preferences.
Potential limitations
This study was not randomized to treatment, and treating dermatologists may have used MMS for higher-risk tumors whose characteristics were unmeasured, and could have affected the risk of recurrence. Although propensity adjustments did not alter conclusions in the parent study, 4 this selection bias may have decreased any observed benefit of MMS. By judging any tumor that was not classifiable as one for which recurrence was more likely, the study sample may contain more tumors that would not recur regardless of how they were treated. This situation was likely uncommon, however, because the overall number of tumors judged appropriate for MMS (74%) is almost identical to that reported elsewhere. 15 The study was conducted at 2 sites within 1 dermatology department in a single city, which could affect generalizability. Also, we did not detect increased risk of recurrence in tumors with some features conventionally believed to increase risk (e.g., tumors in the H zone of the face 14 ) , which may be related to insufficient power, because recurrence rates overall were low. Finally, the AUC were guided not only by the goal of reducing recurrence rates, but also for tissue conservation, which was not considered in this study.
In conclusion, we tested and confirmed the ability of the AUC for MMS to identify KCs for which recurrence rates will be lower than after excision. The absolute difference in recurrence rates between treatments is small, however. New studies should determine more specifically the subgroups of patients and tumors for which tumor recurrence rates after MMS are substantially improved. Echoing the explicit statement of the Task Force that composed the AUC, we hope that our work will guide future reassessments and refinements of the criteria. J AM ACAD DERMATOL VOLUME 76, NUMBER 6
